» Articles » PMID: 26849038

Imaging of Oligodendroglioma

Overview
Journal Br J Radiol
Specialty Radiology
Date 2016 Feb 6
PMID 26849038
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Oligodendroglioma are glial tumours, predominantly occurring in adults. Their hallmark molecular feature is codeletion of the 1p and 19q chromosome arms, which is not only of diagnostic but also of prognostic and predictive relevance. On imaging, these tumours characteristically show calcification, and they have a cortical-subcortical location, most commonly in the frontal lobe. Owing to their superficial location, there may be focal thinning or remodelling of the overlying skull. In contrast to other low-grade gliomas, minimal to moderate enhancement is commonly seen and perfusion may be moderately increased. This complicates differentiation from high-grade, anaplastic oligodendroglioma, in which enhancement and increased perfusion are also common. New enhancement in a previously non-enhancing, untreated tumour, however, is suggestive of malignant transformation, as is high growth rate. MR spectroscopy may further aid in the differentiation between low- and high-grade oligodendroglioma. A relatively common feature of recurrent disease is leptomeningeal dissemination, but extraneural spread is rare. Tumours with the 1p/19q codeletion more commonly show heterogeneous signal intensity, particularly on T2 weighted imaging; calcifications; an indistinct margin; and mildly increased perfusion and metabolism than 1p/19q intact tumours. For the initial diagnosis of oligodendroglioma, MRI and CT are complementary; MRI is superior to CT in assessing tumour extent and cortical involvement, whereas CT is most sensitive to calcification. Advanced and functional imaging techniques may aid in grading and assessing the molecular genotype as well as in differentiating between tumour recurrence and radiation necrosis, but so far no unequivocal method or combination of methods is available.

Citing Articles

Mental fatigue and cognitive functioning in patients presenting with non-enhancing gliomas.

Neimantaite A, Vecchio T, Ryden I, Harba D, Jakola A, Smits A Acta Neurochir (Wien). 2025; 167(1):63.

PMID: 40056223 PMC: 11890337. DOI: 10.1007/s00701-025-06434-6.


Impact of Sex Hormones on Glioblastoma: Sex-Related Differences and Neuroradiological Insights.

Rossi J, Zedde M, Napoli M, Pascarella R, Pisanello A, Biagini G Life (Basel). 2025; 14(12.

PMID: 39768232 PMC: 11677825. DOI: 10.3390/life14121523.


Multidisciplinary quantitative and qualitative assessment of IDH-mutant gliomas with full diagnostic deep learning image reconstruction.

Ruff C, Bombach P, Roder C, Weinbrenner E, Artzner C, Zerweck L Eur J Radiol Open. 2024; 13:100617.

PMID: 39717474 PMC: 11664152. DOI: 10.1016/j.ejro.2024.100617.


Preoperative prediction of diffuse glioma type and grade in adults: a gadolinium-free MRI-based decision tree.

Azizova A, Prysiazhniuk Y, Wamelink I, Cakmak M, Kaya E, Wesseling P Eur Radiol. 2024; 35(3):1242-1254.

PMID: 39425768 PMC: 11836213. DOI: 10.1007/s00330-024-11140-5.


Revisiting oligodendroglioma grading in the 2021 WHO classification: calcification and larger contrast-enhancing tumor volume may predict higher oligodendroglioma grade.

Lee D, Choi K, Han K, Choi S, Lee N, Ahn S Neuroradiology. 2024; 66(9):1527-1535.

PMID: 39014271 DOI: 10.1007/s00234-024-03430-y.


References
1.
Lev M, Ozsunar Y, Henson J, Rasheed A, Barest G, Harsh 4th G . Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol. 2004; 25(2):214-21. PMC: 7974605. View

2.
Law M, Yang S, Wang H, Babb J, Johnson G, Cha S . Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol. 2003; 24(10):1989-98. PMC: 8148904. View

3.
Ishiuchi S, Tamura M . Central neurocytoma: an immunohistochemical, ultrastructural and cell culture study. Acta Neuropathol. 1997; 94(5):425-35. DOI: 10.1007/s004010050729. View

4.
Walker C, du Plessis D, Fildes D, Haylock B, Husband D, Jenkinson M . Correlation of molecular genetics with molecular and morphological imaging in gliomas with an oligodendroglial component. Clin Cancer Res. 2004; 10(21):7182-91. DOI: 10.1158/1078-0432.CCR-04-0681. View

5.
White M, Zhang Y, Kirby P, Ryken T . Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas?. AJNR Am J Neuroradiol. 2005; 26(4):784-90. PMC: 7977108. View